Not yet recruiting

2

86

RoW

BL-M07D1, PD-1 monoclonal antibody, Capecitabine

Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma

06/26

06/26

Completed

2

80

Europe

Chemoradiotherapy, Radiochemotherapy, Chemoradiation, Ipilimumab, Yervoy®, Nivolumab, Opdivo®

Johannes Laengle, MD, PhD, Bristol-Myers Squibb

Rectal Cancer

03/24

03/24

Recruiting

2

150

RoW

mCapOX plus cetuximab, mFOLFOX6 plus cetuximab

West China Hospital, First Affiliated Hospital of Chongqing Medical University

Colo-rectal Cancer, Capecitabine, Cetuximab

06/25

06/26

Recruiting

2

33

RoW

AK104, Cadonilimab, Capecitabine, Neoadjuvant Radiotherapy

Sun Yat-sen University, Akeso, Haplox Biotechnology Co., Ltd.

Locally Advanced Rectal Cancer

06/24

01/25

Not yet recruiting

2

360

RoW

QLS31905, Oxaliplatin, Capecitabine, Gemcitabine, Cisplatin, QL1706, Chemotherapy drug

Qilu Pharmaceutical Co., Ltd.

Advanced Solid Tumor

06/26

12/27

Active, not recruiting

2

284

RoW

Docetaxel, Oxaliplatin, Leucovorin, Fluorouracil, Capecitabine

Ukrainian Society of Clinical Oncology

Gastric Cancer

07/24

07/29

Not yet recruiting

2

100

NA

PD-1 inhibitor, Tislelizumab, Capecitabine, Xeloda, Long-course radiation therapy

Peking Union Medical College Hospital

Locally Advanced Rectal Cancer

07/24

12/29

Not yet recruiting

2

20

RoW

capecitabine, tislelizumab, thymalfasin, long-term radiotherapy

Beijing Friendship Hospital, Peking Union Medical College Hospital

Locally Advanced Rectal Cancer

07/24

07/27

Not yet recruiting

2

310

RoW

Extended Dosing Interval - A, Extended Dosing Interval - B, Extended Dosing Interval - C, Standard of Care - A, Standard of Care - B, Standard of Care - C

National University Hospital, Singapore

Carcinoma, Hepatocellular, Gastric Adenocarcinoma, GastroEsophageal Cancer, Oesophageal Cancer, Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma

03/29

12/29

Recruiting

2

73

RoW

SHR-1701；Capecitabine；Oxaliplatin

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Locally Advanced Rectal Cancer

07/24

10/26

Recruiting

2

50

RoW

CAPEOX, Pembrolizumab, Keytruda, Capecitabine/ 5-FU, CAPEOX/Pembrolizumab, Pembrolizumab alone, Surgical resection

National Cancer Centre, Singapore, Merck Sharp & Dohme LLC

Colorectal Cancer

08/24

08/24

Not yet recruiting

2

70

NA

letrozole, capecitabine

Assiut University

Metastasis Breast

08/24

05/25

Recruiting

2

126

RoW

Intensity-modulated radiotherapy concurrent with capecitabine

Sun Yat-sen University

Metastatic Esophageal Squamous Cell Carcinoma

08/24

09/25

Active, not recruiting

2

40

Europe

Durvalumab, Tremelimumab, Capecitabine

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Biliary Tract Cancer (CCA), Intrahepatic Cholangiocarcinoma, Hilar Cholangiocarcinoma, Distal Cholangiocarcinoma, Gall Bladder Carcinoma

12/24

06/25

Recruiting

2

312

US

Capecitabine, 5-fluorouracil, Leucovorin calcium, Irinotecan, Oxaliplatin, Long Course Chemoradiotherapy, Computed Tomography, Magnetic Resonance Imaging, Sigmoidoscopy, biopsy

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)

Locally Advanced Rectal Carcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8

09/24

09/32

Not yet recruiting

2

174

Europe

Blood sample, Quality of life questionnaires, Biopsy, Regorafenib, Regorafenib + metronomic chemotherapy

Centre Hospitalier Universitaire de Besancon, Groupement Interrégional de Recherche Clinique et d'Innovation

Metastatic Colorectal Cancer

09/27

09/28

Recruiting

2

57

RoW

Tucatinib, Tukysa, Pembrolizumab, Keytruda, Trastuzumab, Herceptin, Capecitabine, Xeloda

Breast Cancer Trials, Australia and New Zealand

Breast Cancer, HER2-positive Breast Cancer

09/24

09/25

Not yet recruiting

2

54

 

metronomic chemotherapy

Jiangmen Central Hospital; Jiangmen Central Hospital, none

nasopharyngeal carcinoma

 

 

Recruiting

2

52

Europe

Atezolizumab, Therasphere, XELOX, Bevacizumab

Federation Francophone de Cancerologie Digestive

Metastatic Colorectal Cancer, pMMR, MSS, Immune Checkpoint Inhibitor, Internal Radiotherapy

10/24

10/24

Recruiting

2

83

RoW

Arterial chemoembolization, Tislelizumab Injection, XELOX, Pelvic MRI, Laparoscopic radical resection of rectal cancer

The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Second Affiliated Hospital, School of Medicine, Zhejiang University

Rectal Neoplasms

11/24

10/25

Recruiting

2

52

RoW

Tislelizumab + Capecitabine, Best supportive care

Yanhong Deng

Metastatic Colorectal Cancer，NED

02/25

11/27

Recruiting

2

44

US

Capecitabine, Ro 09-1978/000, Xeloda, Fluorouracil, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Laboratory Biomarker Analysis, Pharmacological Study, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy, Zoledronic Acid, [1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene]bisphosphonic Acid, CGP 42446, CGP42446A, NDC-Zoledronate, Reclast, ZOL 446, Zometa

University of Nebraska, National Cancer Institute (NCI)

Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage I Pancreatic Cancer AJCC v6 and v7, Stage IA Pancreatic Cancer AJCC v6 and v7, Stage IB Pancreatic Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7, Stage IIA Pancreatic Cancer AJCC v6 and v7, Stage IIB Pancreatic Cancer AJCC v6 and v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7

12/27

12/27

Recruiting

2

55

US

Capecitabine tablets + temozolomide tablets + SIR-Spheres, SIR-Spheres

Abramson Cancer Center of the University of Pennsylvania, Roswell Park Cancer Institute, CARTI

Neuroendocrine Tumor Grade 2, Liver Metastases

12/24

12/25

Recruiting

2

93

RoW

PD-1 antibody, Toripalimab, Capecitabine, Xeloda, 5FU, folinic acid, Oxaliplatin, Irinotecan, Raltitrexed, Radiation

Fudan University

Recurrent Rectal Cancer

12/24

12/25

Not yet recruiting

2

63

NA

Inetetamab, pyrotinib, chemotherapy, Inetetamab for injection, Pyrotinib maleate

Fujian Medical University

HER2-positive Recurrent/Metastatic Breast Cancer

12/24

12/25

Recruiting

2

58

Europe

Durvalumab (MEDI4736)

Grupo Espanol Multidisciplinario del Cancer Digestivo, AstraZeneca, Vall d'Hebron Institute of Oncology (VHIO)

Rectal Cancer

12/24

03/25

Active, not recruiting

2

10

Europe, US

Ruxolitinib, INCB018424, Jakafi®, Capecitabine, Xeloda®, Regorafenib, Stivarga®

Incyte Corporation

Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer, Lung Cancer

12/24

12/24

Recruiting

2

126

RoW

Toripalimab, JS001, IMRT to the nasopharynx and neck, RT to the nasopharynx and neck, Gemcitabine and Cisplatin Chemotherapy, GP regimen chemotherapy, Adjuvant chemotherapy with Capecitabine, Xeloda

Fudan University, Fudan University Eye and ENT Hospital, Anhui Provincial Hospital, Sir Run Run Shaw Hospital, Hangzhou Cancer Hospital, Ningbo Medical Center Lihuili Hospital, The First People's Hospital of Changzhou, Cancer Hospital of Chinese Academy of Medical Science, Shenzhen Center, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Nanfang Hospital of Southern Medical University, Shenzhen People's Hospital, First Affiliated Hospital of Xi'anJiaotong Univerisity, Guangzhou Panyu Central Hospital

Nasopharyngeal Carcinoma

12/24

12/26

Not yet recruiting

2

106

 

Camrelizumab + Oxaliplatin + 5-FU or Capecitabine or Tegafur

Harbin Medical University Cancer Hospital; Harbin Medical University Cancer Hospital, Self-funded

MSI-H/dMMR advanced gastric cancer

 

 

Recruiting

2

125

RoW

TSL-1502 capsules(low dose), TSL-1502 capsules(high dose), Investigator's choice of chemotherapy

Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.

Breast Cancer Metastatic

12/24

06/26

Not yet recruiting

2

25

NA

Tislelizumab, Capecitabine, Oxaliplatin

The First Affiliated Hospital of Zhengzhou University

MSI-H Colorectal Cancer, Tislelizumab, Oxaliplatin, Capecitabine

12/24

01/27

Recruiting

2

924

Europe

Capecitabine, MEDI4736, Trastuzumab, Rucaparib, Ramucirumab

Royal Marsden NHS Foundation Trust, MedImmune LLC, Clovis Oncology, Inc., Eli Lilly and Company, AstraZeneca

Adenocarcinoma of the Oesophagus, Adenocarcinoma of the Gastro-oesophageal Junction, Adenocarcinoma of the Stomach

03/25

06/27

Recruiting

2

92

RoW

Cadonilimab, Oxaliplatin, Capecitabine

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Rectal Cancer, MSS

03/25

03/26

Recruiting

2

531

Europe, Canada, Japan, US, RoW

Datopotamab deruxtecan (Dato-DXd), DS-1062a, Saruparib, AZD5305, Durvalumab, MEDI4736, IMFINZI, Capecitabine, Xeloda, 5-Fluorouracil, Adrucil, Volrustomig, MEDI5752, Carboplatin, Paraplatin, Leucovorin LV, Folinic acid, Bevacizumab, Avastin, Rilvegostomig, AZD2936, Prednisone/ prednisolone, Prednisolone

AstraZeneca, Daiichi Sankyo

Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer, Biliary Tract Cancer

08/26

08/26

Active, not recruiting

2

38

US

FOLFOXIRI, FOLFOX regimen, XELOX, IMRT, Intensity-modulated radiotherapy (IMRT)

Stanford University

Rectal Cancer

01/24

01/26

Recruiting

2

25

Europe

Capecitabine, Xeloda, Oxaliplatin, Oxaliplatin Accord, Retifanlimab, INCMGA00012

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Incyte Corporation

Gastric Adenocarcinoma, Esophageal Adenocarcinoma

05/25

11/29

Recruiting

2

356

RoW

capecitabine and trastuzumab, endocrine therapy and trastuzumab

Fudan University

Breast Cancer

05/25

05/27

Active, not recruiting

2

21

RoW

neoadjuvant chemo-hypofractionated radiotherapy plus PD-1 antibody (Tislelizumab)

Jiangsu Cancer Institute & Hospital

Gastric or Gastroesophageal Junction Adenocarcinoma

06/25

12/25

Not yet recruiting

2

48

NA

Durvalumab, MEDI 4736, FOLFOX, mFOLFOX6, Short Course Radiotherapy (Arm A), Long course chemoradiation (Arm B), Capecitabine

Liz-Anne Lewsley, University of Glasgow, AstraZeneca, NHS Greater Glasgow and Clyde

Rectal Cancer, Rectal Adenocarcinoma, Rectal Neoplasms

06/25

12/25

Not yet recruiting

2

204

 

Bevacizumab 7.5mg/kg, administered on the first day, intravenous injection; oxaliplatin 130mg/m^2 administered on the first day, intravenous injection; capecitabine 1g/m^2 twice a day, orally, continuously 14 days, 1 week off, 3 weeks for a cycle ;Bevacizumab 7.5mg/kg, administered on the first day, intravenous injection; oxaliplatin 130mg/m^2 administered on the first day, intravenous injection; capecitabine 1g/m^2 twice a day, orally, continuously 14 days, 1 week off; sintilimab 200mg, administered on the first day, intravenous injection, 3 weeks for a cycle.

Beijing Cancer Hospital; Beijing Cancer Hospital, Innovent Biopharmaceutical (Suzhou) Co., Ltd. will provide sintilimab according to the expected enrollment plan of the research center

Colorectal cancer liver metastases

 

 

Recruiting

2

74

 

Capecitabine is administered orally

Eye & ENT Hospital of Fudan University; Eye & ENT Hospital of Fudan University, self-financing

hypopharyngeal carcinoma

 

 

Recruiting

2

60

RoW

Taurine, Sintilimab, XELOX regimen, SOX regimen, FOLFOX regimen

Tang-Du Hospital

Gastric Cancer

07/25

07/25

Recruiting

2

240

Europe

Valproic acid, Simvastatin 20mg, Gemcitabine 1000 mg, Nab paclitaxel, Cisplatin, Capecitabine

National Cancer Institute, Naples

Adenocarcinoma of the Pancreas

08/25

06/26

Not yet recruiting

2

30

China

surufatinib combined with durvalumab and capecitabine

Shanghai Xuhui Central Hospital ; Shanghai Xuhui Central Hospital, Special funds

biliary tract cancer

 

 

Recruiting

2

56

RoW

Total Neoadjuvant Chemoradiotherapy, Total Neoadjuvant Treatment

Shanghai Zhongshan Hospital

Rectal Cancer

08/25

08/27

Recruiting

2

116

RoW

Fruquintinib+ chemotherapy, Bevacizumab+ chemotherapy

Fudan University

Metastatic Colorectal Cancer

09/25

09/25